STUDY DESIGN AND METHODS:
A novel HCV core-specific antibody was assayed on random single donations from 2007 first-time blood donors who tested negative for anti-HCV and HCV RNA on routine screening. Sample collection broke the code between donations and donors for ethical reasons.
RESULTS: Forty-two donations (2.1%) displayed reactivity in the novel test. The specificity of the reactivity was evaluated by a peptide inhibition assay, and testing against additional nonoverlapping HCV core peptide epitopes and other HCV antigens was performed on these samples. Six donations (14.3%; 0.30% from the total) were considered to contain anti-HCV after such supplemental testing. HCV RNA detection was also performed in peripheral blood mononuclear cells (PBMNCs) and serum or plasma samples from reactive donors after virus concentration by ultracentrifugation. HCV RNA tested negative in all PBMNCs samples, and a very low amount of viral genome was detected in serum or plasma concentrates from three anti-HCV corereactive donors (7.1%) but not among concentrates from 100 randomly selected nonreactive donors. Sequencing of these polymerase chain reaction products revealed differences between the isolates that excluded partially sample contamination from a common source.
CONCLUSION: These findings argue in favor of an ongoing occult HCV infection among these blood donors and account for some rather low, but perhaps not negligible, infection risk for such donations. Future studies involving larger samples of donations from traceable donors would enlighten the significance of these findings for the viral safety of the blood supply. testing are mandatory as part of blood donor screening, and both markers must test negative for the donor to be accepted. However, the risk of HCV transmission, although very low, is not zero. [3] [4] [5] Occult HCV infection (OCI) has been reported and was characterized by the presence of HCV RNA in peripheral blood mononuclear cells (PBMNCs) and/or liver tissue among patients who tested negative for both anti-HCV and HCV RNA in serum or plasma. 6 HCV RNA was also detected in serum after concentrating viral particles by ultracentrifugation, which increases the sensitivity of the testing. 7 OCI has been found among patients with cryptogenic hepatitis and chronic renal diseases, but also in 3.3% of individuals from the general population displaying normal liver function tests. 6, 8, 9 A proportion of these cases tested in addition positive by a novel anti-HCV core-specific antibody test, 10 but this test has not been yet compared with conventional screening assays among blood donors. Actually, the occurrence of OCI among first time blood donors has never been communicated. The aims of this prospective, collaborative study were: 1) to investigate the frequency and the significance of the finding of HCV core-specific antibody reactivity among blood donors testing negative for anti-HCV and HCV RNA in screening and 2) to assess whether such reactivity correlates with the finding of HCV RNA sequences in PBMNCs and/or serum or plasma concentrated by ultracentrifugation.
PATIENTS AND METHODS

Study population
A total of 2012 consecutive, unselected, first-time unpaid blood donors admitted for screening of blood donation markers were prospectively enrolled from October 2014 to July 2015 at three transfusion centres: Red Cross Spain (n 5 823) and the transfusion centers from the communities of Madrid (n 5 1094) and Castilla y Le on (n 5 95). The inclusion criteria were: 1) first-time blood donors who agreed to sign the informed consent and 2) availability of sufficient serum, plasma, and PBMNC samples collected at the time of study entry. Units testing positive for markers of HCV infection (anti-HCV and/or HCV RNA), human immunodeficiency virus (HIV; anti-HIV and/or HIV RNA), hepatitis B virus (HBV) infection (HBV surface antigen and/or DNA), or other infections (syphilis, malaria) were not excluded. Five donations were excluded because the lack of PBMNC samples, and the final population consisted of 2007 donors of whom 1104 were males and 903 females. No other demographic data were provided to the investigators, and the link between unit and donor identification was broken before sending the materials to the laboratories involved in the study. This procedure prevented communication of results to the donors, although also the obtaining of additional samples and the design of follow-up studies. The study was approved by the Ethic Committee of the Hospital Cl ınico San Carlos Testing of anti-HCV core-specific antibody HCV core-specific antibody was tested by an immunoassay with enhanced sensitivity (anti-hcv core highsensitivity enzyme-linked immunosorbent assa (ELISA kit, DIATER Laboratories) using as antigen a single peptide from a conserved HCV core region (Amino Acids 5-19). The test is based on an investigational anti-HCV core immunoassay. 10 According to current CE labeling regulations, calculation of the cutoff value was referred to the formula CO 5 0.5 3 (NC 1 0.1 3 PC), where NC is the mean value for the negative control (six replicas) and PC is the mean value for the positive control (two replicas) after assaying more than 1000 positive, negative, and interfering samples in parallel with two CE-marked methods. Testing was performed in prediluted samples (1/10) according to supplier's instructions, and sample-to-cutoff absorbance ratios (absorbance index [AI]) of at least 1.2 were considered reactive. The assay has shown 100% diagnostic sensitivity in chronic infections by HCV Genotypes 1 to 6, and specificities of 100 and 99.7% among blood donors and clinical specimens, respectively.
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Anti-HCV core-reactive samples were further analyzed by: 1) peptide inhibition assay, 10 the percentage of inhibition (PI) being calculated by the formula PI 5 1 -[(absorbance of sample with 100 mg/mL of peptide)/(absorbance of sample without peptide)] 3 100; 2) a supplemental anti-HCV core peptide immunoassay based on peptides spanning Amino Acids 21 to 40 and 101 to 120 of the HCV core sequence (European Patent EP2258714B1), the testing procedure being exactly as described for Peptides 5 to 19; 10-12 and
3) conventional confirmatory testing by a commercial immunoblot assay (INNO-LIA HCV-Score, Fujirebio Europe). Reactivity for anti-HCV core was thought specific when the PI was at least 50%. Concurrent reactivity in the supplemental anti-HCV core peptide test and the finding of reactivity (positive or indeterminate results) by immunoblot were also taken into account for the final interpretation. Samples testing positive by at least two of the three supplemental tests were considered positive for anti-HCV.
HCV RNA detection in PBMNCs and in ultracentrifuged serum and plasma samples Nonrefrigerated blood samples were received at FEHV within 24 hours after extraction. Upon arrival, serum samples were obtained from coagulated blood, made into aliquots, and stored at 2308C. PBMNCs and plasma were isolated from anticoagulated blood by density gradient centrifugation (Biocoll, Biochrom). Plasma was aliquoted and stored at 2308C, while cells were washed three times in phosphate-buffered saline and thereafter stored in solution (RNAlater, Ambion) also at 2308C.
HCV RNA detection was performed by laboratory personnel who were blinded to the serologic status of the donors. Each polymerase chain reaction (PCR) run included a maximum number of 10 samples along with negative controls (repeatedly HCV RNA-negative sera and PBMNCs samples) and reagent blanks in which total RNA was replaced with PCR-grade water. Negative controls and blanks were coprepared with the samples and accompanied them through the entire PCR process. As positive controls, HCV RNA-positive sera and PBMNCs from patients with chronic HCV infection were used. The guidelines of Kwok and Higuchi 13 were strictly observed for avoiding contaminations.
Total RNA was isolated from PBMNCs with an RNA isolation system (SV Total, Promega). After precipitation, pellets were dissolved in diethylpyrocarbonate (DEPC)-treated water and RNA concentration was determined by spectrophotometry. Total RNA was extracted from 250 lL of serum using reagent (Trizol LS, Invitrogen), and the pellet was dissolved in 10 lL of DEPC-water. In addition, 2 mL of serum and 2 mL of plasma were ultracentrifuged 7 over a 10% sucrose cushion at 100,000 3 g for 17 hours at 48C. Pellets were dissolved in 250 lL of TE buffer (10 mmol/L tris(hydroxymethyl)aminomethane-HCl, 10 mmol/L ethylenediaminetetraacetic acid; pH 7.5) and total RNA was iso- RT was performed at 618C for 30 minutes; the mixture was then heated at 958C for 2 minutes; and then PCR was performed for 50 cycles of 958C for 0 seconds (denaturation), 558C for 12 seconds (annealing), and 728C for 10 seconds (extension). The fluorescence was measured at the end of each annealing step. A standard curve constructed with 10-fold dilutions of a synthetic HCV RNA was used for quantification. The lower limit of HCV RNA detection of the assay was 10 IU/mL (mean threshold cycle [Ct], 39.32) with a lower limit of quantification of 100 IU/mL (mean Ct, 35.64), as determined by testing serial dilutions of HCV RNA-positive serum sample, in which HCV RNA quantification was previously assessed by an HCV test (Cobas TaqMan, Roche Diagnostics). PCR testing was considered positive if the Ct level was obtained at no more than 39 cycles, and quantification was achieved by reference to the standard curve.
To further confirm the results, the remaining total RNA extracted from positive samples was sent to a second laboratory (Centro Nacional de Microbiolog ıa [CNM]) and used to perform an additional amplification of the 5 0 NC region of the HCV genome by nested RT-PCR. 14 The PCR products obtained (235 bp) were also purified and sequenced as described below. The sequences of the primers used in these tests are given in Table 1 .
Sequencing and sequence analysis
PCR products from positive samples obtained either at the FEHV or at the CNM were purified by PCR clean-up 
RESULTS
Infectious testing at the transfusion centers
Anti-HCV reactivity was recorded in two donors (0.1%), but none of them coud be confirmed on supplemental immunoblot testing. Therefore, all donors finally tested negative for anti-HCV. Markers of other infectious diseases were detected in six donors (0.3%): HBV DNA in two (0.1%), malaria in two (0.1%), syphilis in one, and cytomegalovirus in one. None of the 2007 donors gave a HCV NAT yield.
Anti-HCV testing
Forty-two samples (2.1%) displayed reactivity in the anti-HCV core test, and the eight samples reacting for any infectious marker in the blood bank screening did not account among them. 
HCV RNA detection
First, HCV RNA was tested in 250 lL of serum, in 2 mL of ultracentrifuged serum, and in PBMNCs from the 42 anti-HCV core-reactive donors and from 100 anti-HCV corenegative donors. RNA testing was negative in all sera (250 lL) and PBMNCs, but was positive (Ct value, 37.11; 10-100 IU/mL) in the 2 mL of ultracentrifuged serum from one donor who tested indeterminate for anti-HCV by immunoblot (Donor 26, Overall, three of 42 (7.1%) anti-HCV core-reactive donors displayed low amounts of circulating viral RNA, while none of the 100 anti-HCV core-negative donors tested positive (p 5 0.025). HCV RNA was also tested in ultracentrifuged serum, plasma, and PBMNC samples from the two donors yielding reactivity for anti-HCV in the screening tests at the blood banks, and all samples tested negative.
Sequencing and sequence analysis
Analysis of the sequences of the PCR products identified all isolates as HCV Genotype 1b (BLAST analysis, NCBI). Donors 14 and 19 shared an identical nucleotide sequence for the genome fragments amplified independently in two laboratories. Identity reached 100% in the BLAST analysis performed with 94 sequences of the NCBI database, including the sequence used as reference in the alignment (Fig. 1) . In contrast, the sequence from Donor 26 displayed six nucleotide changes (C114G, A116C, G253C, G256C, G271C, and A276G) in comparison with the former. Substitutions C114G and G256C were detected in fragments amplified from serum but not from plasma, and substitutions A116C and G253C were found only in the product amplified at one of the two laboratories (CNM).
Liver function tests
Abnormal liver function tests were recorded in 306 of 2007 (15.3%) donors. Altered transaminase levels were detected in one of five (20%) anti-HCV core-positive donors and in five of 37 (13.5%) among the remaining anti-HCV corereactive donors (four males and two females). The frequency of anti-HCV core reactivity did not display significant differences in regard to this feature (6/306 with altered values vs. 36/1701 with normal values).
DISCUSSION
The prevalence of anti-HCV among blood donors declined dramatically in Spain during the past decade and was recently reported 0.013% from 1.7 million first-time donors. 15 Among the general population of adults, the overall prevalence is more than 100-fold higher (1.8%). 16 The small size of the sample studied might account for the lack of anti-VHC-positive donors resulting in this study from the screening performed at the transfusion centers.
In contrast, anti-HCV core testing selected 42 donors to investigate, and supplemental studies could identify, according to the criteria explained, five donors displaying prior contact with HCV but not actual infection and three donors displaying OCI (Table 3 ). The yield of this alternative testing was 0.39% (8/2007 ). Most of the donors (34/42, 81%) lacked, therefore, any evidence of prior contact with HCV, and these false-positive cases represented 1.7% of the sample studied.
The novel assay could actually detect anti-HCV where some current assays did not, including some assays using a sample dilution lower than 1:10. These findings would suggest that minute amounts of antibody directed toward an epitope present in the single peptide used could be more prone to be detected when the specific activity of the target is not diluted in the multiantigen design of the solid phase of a conventional immunoassay (European Patent EP2258714B1). 10 The results obtained by immunoblot supported the interpretation for seven samples, and recording of isolated reactivity to core antigens by INNOLIA among four of them was of interest. 17 This advantage was, however, jeopardized by the finding of a large number of falsepositive results, which might be elicited by some human protein displaying cross-reactivity with epitopes of this region of the HCV core protein. [18] [19] [20] Alternatively, presence of maturation-altered or low-avidity anti-HCV [21] [22] [23] could explain the results, as suggested previously for OCI. 10 Although sample concentration by ultracentrifugation does not account among the procedures standardized for HCV diagnosis by PCR, it offers a valuable research tool for improving the knowledge of the natural history of the HCV infection. Sample contamination, either from external sources before testing or from sample to sample during testing, must be carefully considered to discuss the results obtained with this approach. Three facts would support the results of this study in regard to this important issue: 1) positive results were obtained in different runs on different days; 2) negative controls, the rest of the samples included in each PCR run, and 100 anti-HCV-negative donors tested negative; and 3) results were reproduced from the RNA extracts by a second laboratory using a different set of primers and a totally independent aliquot of sample, which is of special significance for supporting the results obtained on Sample 14 (presence of HCV RNA in absence of anti-HCV ). Sequencing confirmed the identity of the products as corresponding to the expected region of HCV Genotype 1b, a viral genotype common in Spain. 24 The fragments displayed, in addition, sequence diversity, which excludes contamination from a common source. Given that the 5 0 NC region of the HCV genome is highly conserved, 25 the sequence identity found for two of the three isolates would fall within the expected and should not be necessarily interpreted as reflecting sample-to-sample contamination. In regard to the interlaboratory discrepancy found in the sequencing of the third isolate, it might represent an artifact of the amplification procedures or could alternatively reflect differential amplification of viral quasispecies present in the sample.
In conclusion, these findings reinforce the notion of OCI as part of the natural history of the HCV infection, [26] [27] [28] [29] [30] although a couple of points remain obscure. First, the discrepancy between the results obtained by PCR on samples of serum and plasma taken at once from the same donor, which perhaps reflects unknown technical issues that could be critical when the viral load is extremely low. Second, the differences found in the sequence of the fragments amplified from samples from Donor 26 at the two participating laboratories, which can respond either to technical or biologic reasons. Third, the weak antibody response and the very low viral load found at once in these donors, which is a feature characteristic of OCI that awaits satisfactory explanation in terms of the putative pathogenic mechanisms leading to it. Although not conclusive yet, the findings of this report suggest that the safety of the blood supply might be improved by the anti-HCV core test used in the study and would justify future studies with larger samples of traceable donors who can be fully characterized and submitted to follow-up studies after selection by the novel test. In regard to such future investigations, collecting and storing PBMNCs for performing cellular recall HCV antigen studies would be of interest, and the evaluation of the outcome of anti HCV core-positive units among their recipients must be regarded in these studies as an ethical commitment.
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